临床实验室测试和痴呆发病率:一个前性队列研究
Yu-Yuan Huang1, Hui-Fu Wang2, Bang-Sheng Wu1
1Department of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Journal of affective disorders
|January 29, 2024
概括
一些常见的实验室检测结果,包括那些表明内分泌,肝脏和功能障碍的结果,与更高的痴呆风险有关. 这些发现可能有助于识别有早期痴呆症预防风险的个体.
科学领域:
- 生物医学研究的研究.
- 临床诊断 临床诊断 临床诊断
- 流行病学 流行病学
背景情况:
- 痴呆症是一个重大的公共卫生挑战和经济负担.
- 了解临床前痴呆症生物标志物对于预防和治疗至关重要.
研究的目的:
- 调查常规实验室测量和痴呆症发病率之间的关联.
- 确定预测早期痴呆风险的潜在生物标志物.
主要方法:
- 利用了来自367,093名英国白人英国人的英国生物库数据.
- 使用后勤回归来分析56个实验室测量和5年痴呆发病率之间的关系.
- 根据实验室测试百分位数计算出痴呆症发病率的调整几率比率.
主要成果:
- 血红蛋白A1C升高 (内分泌失调) 与痴呆发病率增加有关.
- 肝功能障碍的指标 (甲转移酶,白蛋白) 和功能障碍 (尿素,囊素C) 显示与更高的痴呆风险有关.
- 免疫标志物 (中性粒细胞数,淋巴细胞数) 和贫血指标,以及低和高的胰岛素样生长因子1也与痴呆症发病率有关.
结论:
- 通过内分泌,肝脏,脏和免疫系统的多种系统生物标志物与痴呆发病率有关.
- 这些发现表明,各种各样的生物过程有助于痴呆的发病.
- 鉴定的生物标志物可以为未来的痴呆症预防策略提供信息.
更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
14.9K
06:58Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
Published on: January 24, 2020
7.3K
相关概念视频
Dementia
115
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
115
Alzheimer's Disease: Overview
487
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
487
Alzheimer's Disease: Treatment
193
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
193
